EDN1 and hydrops fetalis: Thus, in ED-CRTd vs. NED-CRTd patients, we evaluated: (i) serum levels of inflammatory markers, ET-1, and miR-130a-5p at baseline and at 12-month follow-up and (ii) clinical outcomes in terms of rate of CRTd responders, HF hospitalizations, cardiac deaths, and all-cause deaths.